Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07325864

Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site

investigate the molecular differences between primitive lung cancer and the metastatic site.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

NSCLC Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Disease Lung Cancer (Diagnosis) Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients aged ≥18 years fit enough to tolerate the surgical operation;
  • the operative risk is considered low based on respiratory reserve and cardiac assessment;
  • the patient has clearly expressed willingness to adhere;
  • availability of pathological material for tumor DNA extraction and NGS execution.

Exclusion criteria

  • Women of childbearing age, pregnant or breastfeeding, or intending to become pregnant during the study.
  • Any other illness, metabolic disorder, physical examination, or laboratory findings that constitute a contraindication to study participation.
  • Recent or ongoing severe or clinically significant infection.

Treatment and study plan

Primary outcomes

  1. To investigate the molecular differences between primitive lung cancer and the metastatic site.

    Time frame: From baseline to 18 months

    Tumoral DNA will be extracted from the formalin-fixed paraffin-embedded (FFPE) block containing the highest percentage of tumor cells, with macrodissection, if necessary, to obtain at least 30% of tumor cells. DNA was extracted from FFPE samples. Next-generation sequencing (NGS) analysis will be performed as previously described. Gene amplification is defined by a coverage mean superior to 3SD.

Study contacts

Contact information is provided by the study sponsor or research team.

Luca Bertolaccini

CONTACT

[email protected]

+390257489244

Sponsors and collaborators

Lead sponsor

European Institute of Oncology

Other

Registry information

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jan 8, 2026
Registry last updated
Jan 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.